The latest funding round, led by Decheng Capital, also included participation from investors including Cormorant Asset Management, Surveyor Capital, and the Prader-Willi Research Foundation.
Aardvark Therapeutics completes over $85 million in Series C funding to advance ARD-101 in the treatment of bulimia in patients with Prader-Willi syndrome
Leave a Comment
